4.93
-0.08(-1.60%)
Currency In USD
| Previous Close | 5.01 |
| Open | 5.01 |
| Day High | 5.34 |
| Day Low | 4.6 |
| 52-Week High | 17.2 |
| 52-Week Low | 3.81 |
| Volume | 56,574 |
| Average Volume | 69,104 |
| Market Cap | 6.53M |
| PE | -0.08 |
| EPS | -60.5 |
| Moving Average 50 Days | 5.49 |
| Moving Average 200 Days | 9.86 |
| Change | -0.08 |
If you invested $1000 in Lyra Therapeutics, Inc. (LYRA) since IPO date, it would be worth $5.31 as of June 01, 2025 at a share price of $4.93. Whereas If you bought $1000 worth of Lyra Therapeutics, Inc. (LYRA) shares 3 years ago, it would be worth $17.93 as of June 01, 2025 at a share price of $4.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
GlobeNewswire Inc.
May 07, 2025 11:00 AM GMT
Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with nasal polyps, analysis showed improvements in both
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
GlobeNewswire Inc.
Oct 15, 2024 11:00 AM GMT
-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies f
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
GlobeNewswire Inc.
Sep 27, 2024 11:00 AM GMT
WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic